Previous Article | Next Article 
Journal of Virology, November 1998, p. 8605-8612, Vol. 72, No. 11
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
A Protein Critical for a Theiler's Virus-Induced
Immune System-Mediated Demyelinating Disease Has a Cell
Type-Specific Antiapoptotic Effect and a Key Role in Virus
Persistence
Ghanashyam D.
Ghadge,
Li
Ma,
Shigeru
Sato,
Jong
Kim, and
Raymond P.
Roos*
Department of Neurology, The University of
Chicago, Chicago, Illinois 60637
Received 16 March 1998/Accepted 8 July 1998
 |
ABSTRACT |
TO subgroup strains of Theiler's murine encephalomyelitis virus
(TMEV) induce a persistent central nervous system infection and
demyelinating disease in mice. This disease serves as an experimental model of multiple sclerosis (MS) because the two diseases have similar
inflammatory white matter pathologies and because the immune system
appears to mediate demyelination in both processes. We previously
reported (H. H. Chen, W. P. Wong, L. Zhang, P. L. Ward,
and R. P. Roos, Nat. Med. 1:927-931, 1995) that TO subgroup strains use an alternative initiation codon (in addition to the AUG
used to synthesize the picornavirus polyprotein from one long open
reading frame) to translate L*, a novel protein that is out of frame
with the polyprotein and which plays a key role in the demyelinating
disease. We now demonstrate that L* has antiapoptotic activity in
macrophage cells and is critical for virus persistence. The
antiapoptotic action of L* as well as the differential translation of L* and virion capsid proteins may foster virus persistence in
macrophages and interfere with virus clearance. The regulation of
apoptotic activity in inflammatory cells may be important in the
pathogenesis of TMEV-induced demyelinating disease as well as MS.
 |
INTRODUCTION |
Multiple sclerosis (MS), a chronic
demyelinating disease of unknown cause, is believed to have an immune
pathogenesis that is influenced by the genetics of the host as well as
the environment, perhaps through exposure to a virus infection. DA
strain and other TO subgroup members of Theiler's murine
encephalomyelitis virus (TMEV) induce a persistent central nervous
system (CNS) infection and demyelinating disease in mice that serves as
an experimental model of MS (for a review, see reference
32). The two diseases have similar inflammatory
white matter pathologies, and in both processes the immune
system appears to contribute to the demyelination. The identification
of the molecular determinants of DA-induced disease may increase our
understanding of the pathogenesis of MS. We previously described a
novel protein called L* that is synthesized by the demyelinating
strains of TMEV and plays a key role in the white matter disease
(7, 15). The present study shows that this protein has
an antiapoptotic effect in macrophages and is critical for virus
persistence.
Strains of TMEV, a murine cardiovirus, are divided into two subgroups
on the basis of their markedly different biological activities in
weanling mice. GDVII strain and other members of the GDVII
subgroup of TMEV produce an acute fatal neuronal disease. In
contrast, DA and other members of the TO subgroup of TMEV cause a
biphasic disease with an initial subclinical neuronal infection followed by a chronic demyelinating process. The DA strain persists, with restricted expression (2, 4-6), in CNS glial cells
(30) and microglia (16) for the life of the
mouse.
As is the case with all picornaviruses, an internal ribosome entry site
in the 5' untranslated region of the TMEV genome enables ribosomes to
bypass multiple AUGs (seven in the case of the DA strain) before
initiating translation at the start of a long open reading frame
(nucleotide [nt] 1066 in the case of the DA strain). The one long
open reading frame is used for the synthesis of a polyprotein that is
sequentially cleaved by proteases into structural and nonstructural
proteins. At times, picornaviruses have an additional initiation
codon, downstream of and in frame with the polyprotein's AUG,
that is used in vitro (hepatitis A virus and encephalomyocarditis virus) or in vivo (foot-and-mouth disease virus) to synthesize a
truncated polyprotein (13, 35, 38). The translation strategy of TO subgroup strains is uniquely different from that of other picornaviruses since these strains have an initiation codon (at nt 1079 in the case of DA), 13 nt downstream from the polyprotein's initiating
AUG, that is used in vitro (15) and in vivo (7) to synthesize a 17-kDa protein called L* in a reading frame different from and overlapping that of the polyprotein (see the genome map in
Fig. 1).
We initially suspected that L* might play a role in DA-induced disease
since the nondemyelinating GDVII strains have an ACG rather than an
AUG at the site corresponding to the alternative initiation codon for
L* of DA and therefore do not synthesize L*. Our recent molecular
genetic studies demonstrated that L* was, in fact, critical for the
late demyelinating disease (7). These studies raised the
possibility that ribosomes may initiate at either the
polyprotein's AUG or the L* AUG, depending on the particular
cell type, and that this variation may determine whether abundant
virion capsid proteins are synthesized (leading to a productive and
lytic infection) or whether there is a restrictive and
persistent infection (with the synthesis of L* but few capsid proteins). The present study provides further characterization of the
function of L* and its importance in virus persistence.
 |
MATERIALS AND METHODS |
Cells and viruses.
BHK-21 cells (a baby hamster kidney
cell line) and P388D1 cells (a mouse macrophage cell line) were
obtained from the American Type Culture Collection and used for studies
of virus growth and viral protein synthesis (see below). BHK-21 cells
were grown on Dulbecco's modified Eagle medium containing 10% fetal
bovine serum (FBS), 2 mM L-glutamine, and 0.01%
gentamycin. P388D1 cells were propagated on RPMI 1640 medium containing
15% FBS, 2 mM L-glutamine, and 0.01% gentamycin. Virus
stocks of wild-type DA, wild-type GDVII, and DAL*-1 viruses were
respectively obtained following transfection into BHK-21 cells of
transcripts derived in vitro from a full-length, infectious cDNA clone
of a wild-type DA strain known as pDAFL3 (33), a wild-type
full-length cDNA copy of a GDVII strain known as pGDFL2
(9), and a mutant pDAL*-1 construct in which the only
difference from the wild-type DA virus genome is a mutation of the AUG
at nt 1079 to ACG, which is used to synthesize L* (15) (see
Fig. 1). This mutation in the DAL*-1 mutant virus abolishes the
synthesis of L* but does not change the predicted amino acid sequence
of the polyprotein.
In vitro virus growth cycle and infectivity assays.
BHK-21
cells or P388D1 cells in 35-mm-diameter dishes were adsorbed in
duplicate for 1 h with wild-type or mutant virus at a multiplicity
of infection (MOI) of 10 PFU per cell. Monolayers were washed and
scraped at various times postinfection (p.i.) and then assayed for
infectivity on BHK-21 cells by a plaque assay.
Radiolabeling of infected cells.
Plates (35-mm diameter) of
cells were either mock infected or infected with wild-type or mutant
virus at an MOI of 5 to 10 PFU per cell. After 1 h, the cells were
washed twice with Hanks' balanced salt solution containing calcium,
magnesium, and 2% FBS. Culture medium containing FBS (5% for BHK-21
and 10% for P388D1 cells) and actinomycin D (2 µg/ml) was added. One
hour prior to addition of 50 µCi of
[trans-35S]methionine (ICN Biomedicals), the
medium was replaced with methionine-free Dulbecco's modified Eagle
medium containing one-third the original concentration of FBS. Cells
were labeled with [35S]methionine for various lengths of
time and harvested after the radiolabeling period by lysis with 150 to
300 µl of sample buffer (50 mM Tris [pH 6.8], 2% sodium dodecyl
sulfate [SDS], 0.1% bromophenol blue, 10% glycerol, and 350 mM
-mercaptoethanol). Radiolabeled proteins were separated by
SDS-12.5% polyacrylamide gel electrophoresis and analyzed by
autoradiography.
Assays of apoptosis. (i) DNA fragmentation analysis.
Analysis of chromosomal DNA fragmentation was carried out as described
by Bose et al. (3). Cells (0.5 × 106 to
1 × 106) were lysed in buffer (10 mM Tris [pH 7.5],
100 mM NaCl, 1 mM EDTA, 1% SDS, and 50 µg of proteinase K per ml)
overnight at 43°C. The DNA was extracted with phenol followed by
chloroform-isoamyl alcohol (24:1 [vol/vol] ratio) and then ethanol
precipitated. Following centrifugation at 12,000 rpm in an Eppendorf
centrifuge (model 5415C) at 4°C for 20 min, the DNA pellet was
dissolved in 50 µl of TE (10 mM Tris [pH 8.0], 1 mM EDTA). The DNA
was then analyzed by 2% agarose gel electrophoresis and stained with
ethidium bromide.
(ii) TUNEL staining.
Cells were either mock infected or
infected with virus at an MOI of 5 and harvested at various time
points. Cells were fixed in 4% formalin in phosphate-buffered saline
for 10 min at room temperature. A 50-µl aliquot of the cell
suspension was then dried on a microscope slide overnight. Apoptotic
cells were detected by using an ApopTag in situ apoptosis kit (Oncor,
Gaithersburg, Md.) in accordance with the manufacturer's instructions.
For each virus infection of cells, a total of 40 to 100 cells were
examined for terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling (TUNEL) in randomized microscope fields from three to
four coverslips. Statistical comparisons were made by using the
Newman-Keuls test.
(iii) Hoechst 33342 staining.
Hoechst 33342 staining was
performed as previously described (12).
Animal studies.
Weanling 3-week-old SJL/J mice (Jackson
Laboratory) were inoculated intracerebrally with 0.03 ml of wild-type
or DAL*-1 virus suspension. Animals were sacrificed 1 and 6 weeks
postinoculation. The brain and spinal cord of each animal were removed
and either frozen for analysis of the infectious virus and viral genome
or fixed for pathological evaluation. Homogenates of frozen tissues from four randomly selected animals that had been inoculated 1 week
previously with either wild-type or DAL*-1 virus were subjected to a
plaque assay for determination of the presence of infectious virus. In
addition, for detection of the viral genome as described below, RNA was
extracted from the brain and spinal cord of each of two animals,
inoculated with either wild-type or DAL*-1 virus, at both 1 and 6 weeks
p.i. (n = 8 mice). Formalin-fixed, paraffin-embedded sections of spinal cord from five animals that had been inoculated with
wild-type or DAL*-1 virus 1 and 6 weeks previously (n = 20 mice) were processed and stained with hematoxylin and eosin.
RT-PCR.
Reverse transcription-PCR (RT-PCR) and a previously
published (36) competitive semiquantitative PCR were used to
detect the viral genome as described below. Total RNA was extracted
from the brain and spinal cord, separately, using an Ultraspec II RNA isolation system (Biotecx Laboratories, Inc., Houston, Tex.) in accordance with the manufacturer's directions. RT was performed in a
total volume of 30 µl at 37°C for 90 min with 300 U of SuperScript II Moloney murine leukemia virus RNase H
reverse
transcriptase (GIBCO, Grand Island, N.Y.), first-strand buffer (50 mM
Tris-HCl [pH 8.3], 75 mM KCl, 3 mM MgCl2), 10 mM dithiothreitol, 2 mM each deoxynucleoside triphosphate, 3 µl of a
50-µg/ml solution of random hexamer primers (Promega, Madison, Wis.),
and 5 µg of the extracted RNA. The solution was then heated at 95°C
for 10 min, and 120 µl of distilled H2O was added.
Adjusted amounts of the test cDNAs were then amplified with DA-specific primers that have been previously described (36). The PCR
was performed in a total volume of 100 µl containing 3 µl of the
cDNA generated in the RT reaction, 10× PCR buffer (10 mM Tris-HCl [pH 8.3], 50 mM KCl, 1.5 mM MgCl2), 40 pmol of each primer, 2 mM each deoxynucleoside triphosphate, and 0.5 µl of AmpliTaq DNA
polymerase (5 U/µl; Perkin-Elmer Cetus, Norwalk, Conn.). In the case
of the competitive RT-PCR, the PCR was performed in the presence of a recombinant clone, pDALAPP (42), which contains an insertion in the L coding region of pDAFL3 (so that the amplified pDALAPP product
has a slower electrophoretic mobility than the wild-type DA product).
As previously described (36), the PCR mixture contained an
amount of competitor cDNA sufficient to register an appropriate signal
of the test cDNA and an amount of test cDNA, in 3 to 5 µl of the RT
reaction solution, adjusted to contain a quantity of hypoxanthine
phosphoribosyltransferase cDNA similar to that of companion specimens.
The PCR conditions were as follows: 1 cycle of 94°C for 3 min; 35 to
45 cycles of 94°C for 45 s (52 s for hypoxanthine
phosphoribosyltransferase), 60°C (for the DA cDNA) for 15 s, and
72°C for 45 s; and 1 cycle of 72°C for 5 min. Aliquots of the
PCR products were electrophoresed in 2.5% agarose gels and stained
with 1% ethidium bromide.
 |
RESULTS |
DA virus with a mutation in L* grows in various cell types.
To
determine whether L* affects the ability of DA to grow in various
tissue culture cells, we compared the growth of wild-type DA virus and
DAL*-1 virus (whose genome maps are shown in Fig. 1) in BHK-21 cells and P388D1 cells. The
two viruses had similar one-step growth curves in BHK-21 cells (Fig.
2) and similar titers at 8 and 16 to
18 h after infection of P388D1 cells (Table 1).

View larger version (9K):
[in this window]
[in a new window]
|
FIG. 1.
Diagram of the viral genomes of wild-type DA and DAL*-1
viruses. The 5' untranslated region (5' UTR), the polyprotein coding
region and its processing products, and the 3' UTR are indicated. The
initiation site for the polyprotein at nt 1066 and that for L* at nt
1079 (which is a reading frame different from that of the polyprotein)
are shown, as is the stop UAG codon for L* at nt 1547. DAL*-1 virus has
a C instead of a U at nt 1080 and fails to synthesize L*.
|
|
DA L* prevents premature shutoff of host cell protein
synthesis.
To examine the effect of L* on DA virus infection of
different cell types, we radiolabeled BHK-21 and P388D1 cells
infected with wild-type DA virus or DAL*-1 virus. As expected,
wild-type DA virus infection of cells led to the synthesis of viral
proteins and a progressive shutoff of host cell protein translation in a permissive cell line, BHK-21 (Fig. 3,
lanes 4, 10, and 16). Similar findings with respect to the synthesis of
viral proteins and the shutoff of cellular proteins were obtained
following DAL*-1 virus infection of BHK-21 cells (Fig. 3, lanes 5, 11, and 17).

View larger version (99K):
[in this window]
[in a new window]
|
FIG. 3.
DAL*-1 virus infection of P388D1 cells causes a
premature shutoff of viral and cellular protein synthesis. Shown is an
autoradiogram of P388D1 and BHK-21 cells that were either mock infected
or infected with wild-type DA or DAL*-1 virus and then radiolabeled at
3 to 5 h p.i. (A), 6 to 8 h p.i. (B), or 10 to 18 h p.i.
(C and D). Cells were harvested at the end of the period of
radiolabeling. M, the left-most lane in panel A, is a marker lane for
the viral proteins and contains radiolabeled BHK-21 cells infected with
DA virus.
|
|
As in the case with BHK-21 cells, DA wild-type virus infection of
P388D1 cells led to the synthesis of viral proteins followed
by a
progressive decline in cellular protein synthesis (Fig.
3,
lanes 1, 7, and 13). The radiolabeled L* band indicated that a
significant amount
of L* protein was synthesized by wild-type
virus in both BHK-21 and
P388D1 cells (Fig.
3). As calculated
with a PhosphorImager, the ratio
of L* to VP3 in P388D1 cells
was 0.4 times that in BHK-21 cells,
suggesting that different
cell types vary in their utilization of the
L*-initiating AUG
versus the polyprotein's initiating AUG.
We then examined radiolabeled viral and cellular proteins following
infection of P388D1 cells with DAL*-1 virus. DAL*-1 virus
had an
apparently premature shutoff of synthesis of both viral
and host cell
proteins. There was a much greater inhibition of
host cell protein
synthesis in P388D1 cells after infection with
DAL*-1 (Fig.
3C, lane
14) than after DA wild-type virus infection
(lane 13) at 10 to 18 h p.i., a time when there was relatively
less synthesis of viral
proteins by the mutant than by the wild-type
virus. This finding was a
consistent one, as shown by the results
of a different experiment (Fig.
3D, lanes 19 and 20). The differences
in inhibition of host cell
protein synthesis were not a result
of differences in the wild-type and
mutant virus MOIs, since similar
results were obtained with different
stocks of virus used at the
same MOI (data not shown) and because the
results were cell type
specific (i.e., the changes observed in P388D1
cells were not
seen in BHK-21 cells). The changes were also seen in
J774.1 mouse
macrophage cells and after infection with DA viruses that
contained
various mutations of L* (data not shown).
DA L* inhibits virus-induced apoptosis of P388D1 cells.
The
shutoff of both viral and host cell protein synthesis following P388D1
cell infection with DAL* mutant viruses suggested that the infection
might have induced apoptosis of the cells. To investigate this
possibility, we used ethidium bromide staining of agarose gels to
examine infected P388D1 cells for evidence of DNA fragmentation. Figure
4 shows that 12 h after infection with DAL*-1 (lane 3) or GDVII (lane 4) virus there was
evidence of DNA laddering that was not seen in the mock-infected (lane 1) or wild-type DA virus-infected (lane 2) P388D1 cells or with infection of BHK-21 cells (data not shown) by these viruses. The apoptotic nature of the cell death was confirmed by Hoechst 33342 staining (Fig. 5A to D), which revealed
extensive nuclear condensation and the presence of apoptotic bodies
following infection with DAL*-1 (Fig. 5C) and GDVII (Fig. 5D)
viruses which was rarely seen in mock-infected cells (Fig. 5A) or after
wild-type DA infection (Fig. 5B).

View larger version (90K):
[in this window]
[in a new window]
|
FIG. 4.
DAL*-1 or GDVII virus infection of P388D1 cells
induces DNA laddering. Prominent DNA laddering is seen with DAL*-1
(lane 3) and GDVII (lane 4) virus infections, but little is seen
with wild-type DA virus infection (lane 2) and none is evident with
mock infection (lane 1). Marker lanes show DNA following digestion
with BstEII or HindIII.
|
|

View larger version (107K):
[in this window]
[in a new window]

View larger version (32K):
[in this window]
[in a new window]
|
FIG. 5.
DAL*-1 or GDVII virus infection of P388D1 cells
induces fragmentation of chromatin and double-stranded DNA breaks.
Hoechst 33342 staining shows chromatin fragmentation (arrows) in P388D1
cells 12 h following DAL*-1 (C) or GDVII (D) virus infection,
but this was not evident in mock-infected (A) or wild-type DA-infected
(B) cells. TUNEL staining of P388D1 cells is seen 12 h following
DAL*-1 (G) or GDVII (H) virus infection, but it was not evident in
mock-infected (E) or wild-type DA-infected (F) cells. (I) Histogram of
the percentages of TUNEL-positive cells (mean ± standard error of
the mean) at 12 and 16 h p.i. This representative experiment was
determined from enumeration of cells in five to seven different
microscope fields of three to four coverslips.
|
|
To quantitate the apoptosis, we examined TUNEL-stained P388D1 cells
following mock infection or infection with wild-type DA,
DAL*-1, or
GDVII virus. Figure
5E to I show the results of a representative
experiment in which apoptosis was apparent at 12 h following
infection
with DAL*-1 virus (Fig.
5G and I) (38% of the cells were
apoptotic)
or GDVII virus (Fig.
5H and I) (43%), while there was
little apoptosis
evident at 12 h following wild-type DA virus
infection (Fig.
5F
and I) (6%) or mock infection (Fig.
5E and I)
(1%). Although the
number of TUNEL-positive cells increased at 16 h after infection
(Fig.
5I) with wild-type DA virus (when the apoptosis
value was
approximately 40%), the degree of apoptosis was
significantly
less (
P < 0.01) than that seen following
DAL*-1 or GDVII virus
infection (for which the value was over 85%
at 16 h p.i.). In
addition, the level of apoptosis seen in P388D1
cells at 16 h
after infection with wild-type DA virus was actually
probably
less than 40%, since many cells had already died of a
nonapoptotic
virus-induced cell lysis. An evaluation of the cells at
16 h p.i.
was not possible because of extensive cell death from
lysis. Similar
results were obtained with BSC-1 cells (data not shown),
a relatively
nonpermissive cell line in which GDVII virus has been
reported
to be far more effective at inducing apoptosis than BeAn virus
(which is a TO subgroup strain similar to DA virus) (
11).
There
was little evidence of apoptosis (<5%) following infection of
BHK-21 cells with each of these viruses, even at 24 h p.i., at
which time the cells began to lyse.
These results suggest that all three viruses have some apoptotic effect
but that DAL*-1 has a much more pronounced apoptotic
effect than
wild-type DA virus. Since the only difference in the
proteins produced
following wild-type DA and DAL*-1 virus infection
is the synthesis of
L* by the former, we presume that the reduced
apoptosis in wild-type DA
virus-infected P388D1 cells is attributed
to an antiapoptotic effect of
L*. The increased apoptosis seen
following infection with GDVII
virus compared to that evident
with DA is presumably at least partly
related to the absence of
L* synthesis (since GDVII virus lacks the
L* AUG).
DA L* is important for persistence of virus within the CNS.
Our previous published studies showed that virus with a mutation in L*
was no longer able to induce a late demyelinating disease (7). To clarify whether this failure was a result of the
inability of the mutant virus to grow well in the CNS, we compared the
pathologies and amounts of virus and viral genome in the CNS of animals
following infection with wild-type or DAL*-1 virus.
DAL*-1 virus produced an early acute polioencephalomyelitis that
was not dissimilar to that seen with wild-type virus (Fig.
6). Seven days after infection with
wild-type DA or DAL*-1 virus,
destructive lesions and inflammatory
infiltrates were frequently
seen in the hippocampus (Fig.
6A and B,
respectively) and neuronophagia
and inflammatory cells in the anterior
horns and anterior root
exit zones (Fig.
6C and D, respectively). In
addition, levels
of virus in the brain and spinal cord were similar 7 days after
infection with DA or DAL*-1 virus (Table
1). These results demonstrated
that
DAL*-1 virus (which fails to synthesize L*) is acutely pathogenic
at 1 week p.i. and that within the CNS it replicates as well as
the
wild-type virus. Therefore, the absence of DAL*-1 virus persistence
at
6 weeks p.i. cannot be explained by an absence of early disease.

View larger version (122K):
[in this window]
[in a new window]
|
FIG. 6.
DA and DAL*-1 viruses induce gray matter pathology in
the CNS by 1 week p.i. Shown are sections of the hippocampus (A and B)
and the spinal cord (C and D) from mice infected with wild-type DA
virus (A and C) or DAL*-1 virus (B and D). The large inset in each
panel is a higher magnification of the smaller highlighted
rectangle. Areas of inflammation are shown in the insets in panels A
and C. The insets in panels B and D show regions of neuronophagia in
the anterior horn.
|
|
We next wondered whether the inability of DAL*-1 virus to induce
demyelinating disease is due to the failure of this mutant
virus to
persist, since the demyelinating disease must be accompanied
by virus
persistence (
32). Since the level of infectious DA
virus is
generally very low at the time of occurrence of the demyelinating
disease, we performed RT-PCR on RNA extracted from the spinal
cords of
infected mice. A competitive semiquantitative RT-PCR
showed that the
viral genome was easily detectable and that its
levels in the mouse
brain and spinal cord were comparable 1 week
after infection with
wild-type or DAL*-1 virus (Fig.
7A, Brain
1w and SC 1w, respectively); i.e., the RNA from at least two of
three
animals infected with DAL*-1 had a lower band, corresponding
to the
viral genome, that was similar in intensity to the lower
band of the
viral genome from animals inoculated with DA. At 6
weeks p.i., the
viral genome was present, as determined by competitive
RT-PCR, in the
spinal cords of mice infected with wild-type virus
(Fig.
7A, SC 6w,
DA); however, there was no detectable amplified
viral genome product in
the spinal cords of mice inoculated with
DAL*-1 virus (and only the
upper band, corresponding to the larger,
amplified pDAL product, is
seen) (Fig.
7A, SC 6w, L*-1). A standard
RT-PCR confirmed these
findings, demonstrating that the viral
genome was present in the brain
and spinal cord 1 week after infection
with DAL*-1 virus (Fig.
7B,
Brain 1W and SC 1w, respectively),
but no signal could be detected 6 weeks after infection with DAL*-1
virus (Fig.
7B, SC 6w); in contrast,
the viral genome was present
in the CNS at 1 and 6 weeks after
infection with wild-type DA
virus. As expected from our previously
published results (
7),
there was little if any demyelination
or pathology in animals
inoculated with DAL*-1 virus, while extensive
inflammatory demyelination
was evident in the spinal cords of mice
inoculated with wild-type
virus (data not shown). These data indicate
that DA L* is critically
important for virus persistence and suggest
that DAL*-1 virus
fails to demyelinate because of the inability of the
virus to
persist.

View larger version (40K):
[in this window]
[in a new window]
|
FIG. 7.
DAL*-1 virus and wild-type DA virus induce similar
amounts of viral genome in the CNS early after infection, but the
genome of the former does not persist. (A) Semiquantitative RT-PCR of
RNA extracted from the brains and spinal cords (SC) of mice inoculated
1 week (1w) or 6 weeks (6w) after infection with wild-type (DA) or
DAL*-1 (L*-1) virus or of an uninoculated mouse (N). Each lane
represents brain or spinal cord from an individual mouse. The uppermost
band on each of the gels shows the position of the competitor pDAL,
which has a slower mobility than the lower band, which represents the
DA genome in the CNS specimen. Only one band corresponding to the
competitor pDAL is seen in some lanes because there is no detectable
viral genome in the brain or spinal cord specimen. (B) RT-PCR of RNA
extracted from the brains and spinal cords of mice inoculated 1 or 6 weeks after infection with DA or L*-1 virus.
|
|
 |
DISCUSSION |
DA and other TO subgroup strains of TMEV induce a biphasic disease
with an initial subclinical gray matter neuronal infection followed by
a chronic demyelination. Virus persists, with restricted expression, in
microglia, oligodendrocytes, and astrocytes in the spinal cord. In
contrast, GDVII strains and members of the GDVII subgroup of
TMEV induce an acute fatal gray matter disease with no evidence of
demyelination or virus persistence. The phenotype of TO subgroup
strains is of interest because persistence and the nonlytic restricted
expression of a picornavirus are distinctly unusual and because TO
subgroup-induced demyelinating disease provides an excellent
experimental model of MS.
We were initially interested in clarifying the role of L* because the
L* initiation codon is present in TO subgroup strains but not in
GDVII subgroup strains, suggesting that this protein product might
be important in TO subgroup virus-induced demyelination and
persistence. Of special note were findings from our original DA
sequencing study (26) which demonstrated that among TMEV strains there is greater conservation of the L coding region, which is
the upstream-most part of the polyprotein's coding region and from
which L* is initiated and partly synthesized, at the nucleotide level
than at the amino acid level. In addition, there are between 9 and 11 amino acid mismatches when TO subgroup strains DA and BeAn L are
compared, and there are 11 such mismatches evident when DA and
GDVII L proteins are compared. In contrast, there are only 6 amino
acid mismatches when the first 76 amino acids of DA and BeAn L*
(equivalent to the size of L) are compared, and there are 8 such
mismatches when the first 76 amino acids of DA and GDVII L* are
compared. In other words, the difference in the amino acid sequences of
L among different TMEV strains is greater than the difference in the
amino acid sequences of the corresponding region of L* among these
strains. These findings suggest that TMEV strains have been under
selection pressure to maintain the third codon, presumably in order to
maintain the alternative reading frame of L*. The importance of L* was
confirmed in later studies that showed that L* is synthesized both in
vitro as well as in infected cells (7, 15) and that L* is
critical for the production of the demyelinating disease
(7). The present demonstration that a significant
amount of L* protein is synthesized during infections in BHK-21 cells
again suggests an important role for this protein.
Our results showed that the growth and behavior of DA L* mutant
virus depend on the cell type infected. DAL*-1 virus, which is unable
to synthesize L*, grew well in cells that are very permissive for DA
strain infection, such as BHK-21 cells. In addition, DAL*-1 virus
induced an acute gray matter infection similar to that seen with
wild-type virus infection, and with comparable levels of virus. In
contrast, there were remarkable differences in the growth and behavior
of the wild-type and DAL*-1 viruses following infection of mouse
macrophage cells. Infection of P388D1 cells with DAL*-1 virus induced a
shutoff of host cell protein synthesis at a time when viral protein
production had not reached as high a level as was associated with host
cell shutoff in wild-type virus infection. Further studies showed that
the reason for this premature inhibition of cellular protein synthesis
was the induction of apoptosis in P388D1 cells. Although there was
evidence of apoptosis following infection with DA, the apoptosis seen
following infection with DA L* mutant virus occurred earlier and was
significantly more prominent. The results suggested that the L* protein
inhibits and slows down the apoptotic cell death that is induced in
certain cell types following TMEV infection. The degree of
virus-induced apoptosis in a cell type may depend on the apoptosis
"machinery" that is present in that cell type and also the amount
of L* that is synthesized in the cell (i.e., how much translation
initiation occurs from the AUG codon at N1079 and how much takes place
from the AUG codon at N1066).
Apoptosis has been previously reported in the case of infections with
picornaviruses, including TMEV (11). Tolskaya et al. (39) found that poliovirus infection induces apoptosis, as
well as antiapoptosis, in certain cells under nonpermissive conditions. Jelachich and Lipton (11) reported that TMEV induces
apoptosis under restrictive conditions, with GDVII virus inducing
at least 50-fold more apoptosis than BeAn following infection of BSC-1 cells, a nonpermissive cell line. In addition, Tsunoda et al. (40) described the occurrence of a greater extent of
apoptosis in neurons and microglia in the mouse CNS early after
infection with GDVII than following DA infection. Our data suggest
that the higher level of apoptotic activity reported with strain
GDVII than that evident after infection with a TO subsgroup strain
is at least partly related to the absence of an L* initiation codon in
the GDVII genome (and therefore the absence of L* synthesis in
GDVII virus infections). Obuchi et al. (25) recently
reported that the GDVII strain does not actively replicate in
J774-1 mouse macrophages despite a significant inhibition of cellular
protein synthesis; in contrast, the DA strain grows well in these
cells. The results of the present study suggest that the inoculation of
J774-1 cells with the GDVII strain results in less infectious virus
than does inoculation with the DA strain because GDVII triggers a
more prominent apoptosis in these cells.
Our study demonstrated that L* is important in mediating virus
persistence. This may occur through an interference with the anti-TMEV
cytolytic T-cell response, since that response is absent in mouse
strains that are susceptible to the late demyelinating disease
following infection with the wild-type virus, presumably preventing
virus clearance (17, 18, 29). Recent studies have
demonstrated that this is the case and that L* inhibits the cytolytic
T-cell response 7 days p.i.; i.e., mouse strains which are normally
susceptible to demyelination, normally have high levels of infectious
virus in the CNS (Table 1), and normally fail to generate a
virus-specific cytolytic T-cell response following wild-type DA virus
infection do induce a virus-specific cytolytic T-cell response
following DAL*-1 virus infection (16a). The generation of
this virus-specific cytolytic T-cell response following DAL*-1 virus
infection presumably leads to virus clearance and prevents demyelination from occurring (since virus persistence has been found to
be necessary for the white matter disease [32]).
It may be that the antiapoptotic activity of L* plays a key role
in inhibiting this virus-specific cytolytic T-cell response, since
apoptosis has been implicated in the induction of this response (1) and because the cytolytic T-cell response is believed to involve apoptotic pathways. A direct inhibition of the cytolytic T-cell
response could occur, as has been described in the case of two
orthopoxvirus antiapoptotic proteins that are members of the serpin
family of protease inhibitors (20, 21). Another possibility
is that L* inhibits apoptosis of macrophages, thereby allowing
widespread infection of these cells, with the subsequent elimination of
these antigen-presenting cells at a time critical for effective virus
clearance by the cytolytic T-cell response.
An increased utilization of the L* AUG by ribosomes for translation
initiation and a decreased initiation of translation at the
polyprotein's AUG may limit the production of capsid protein, the
target for the cytolytic T-cell response (17). This relative decrease in synthesis of capsid proteins not only may prevent the
generation of a cytolytic T-cell response but may also favor restricted
virus expression. It may be that there is a greater degree of
initiation of L* translation at nt 1079 in microglia (which are the
major reservoir of virus during the persistent CNS infection
[19] and which have a restricted infection) than in
BHK-21 cells and neurons (i.e., productively infected cells), perhaps
because cell-specific proteins bind the viral genome. In this way, a
cell type-specific regulation of two different initiation codons for
translation can increase the synthesis of either L* (and lead to an
inhibition of virus-induced apoptosis, an inhibition of a
virus-specific cytolytic T-cell response, and restricted virus
expression because of a decrease in viral capsid protein synthesis) or
the polyprotein and capsid proteins.
It is now recognized that apoptosis can play an important role in viral
infections (31) and, in addition, can disturb the immune
system balance, thereby contributing to autoimmune processes (27). A number of investigations have demonstrated that
induction of apoptosis of T cells and macrophages by various mechanisms (e.g., encephalitogenic proteins, peptides, and steroids) alleviates acute experimental allergic encephalomyelitis (EAE) (23, 24, 28), an experimental model of MS. In addition, apoptosis of T
cells during recovery from acute EAE and in brain infiltrates in
chronic EAE has been reported (22), suggesting that an
inhibition of apoptosis may enhance immune-mediated demyelination and
limit recovery (14); some studies, however, suggested that
an inhibition of apoptosis may result in protection against EAE
(34, 41). In an analogous way, there is accumulating
evidence that resolution of an attack of MS is related to apoptotic
activity. Steroids, which induce apoptosis of T cells (37),
alleviate MS as well as EAE. Recent studies of affected CNS regions
(8) and T cells (10) of MS patients
describe abnormalities of the apoptotic pathway. Our studies
indicate a role for apoptosis in a chronic inflammatory
demyelinating disease and, by analogy, suggest that regulation of
apoptosis may also be important in MS disease pathogenesis.
 |
ACKNOWLEDGMENTS |
G.D.G. and L.M. contributed equally to this study.
This work was supported by grants from the National Multiple Sclerosis
Society and the National Institutes of Health.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Neurology (MC 2030), The University of Chicago, 5841 S. Maryland Ave., Chicago, IL 60637. Phone: (773) 702-6390. Fax: (773) 702-7775. E-mail:
rroos{at}drugs.bsd.uchicago.edu.
 |
REFERENCES |
| 1.
|
Albert, M. L.,
B. Sauter, and N. Bhardwaj.
1998.
Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs.
Nature
392:86-89[Medline].
|
| 2.
|
Aubert, C.,
M. Chamorro, and M. Brahic.
1987.
Identification of Theiler's virus infected cells in the central nervous system of the mouse during demyelinating disease.
Microb. Pathog.
3:319-326[Medline].
|
| 3.
|
Bose, R.,
M. Verheij,
A. Haimovitz-Friedman,
K. Scotto,
Z. Fuks, and R. Kolesnick.
1995.
Ceramide synthase mediates daunorubicin-induced apoptosis: an alternative mechanism for generating death signals.
Cell
82:405-414[Medline].
|
| 4.
|
Cash, E.,
M. Chamorro, and M. Brahic.
1988.
Minus-strand RNA synthesis in the spinal cords of mice persistently infected with Theiler's virus.
J. Virol.
62:1824-1826[Abstract/Free Full Text].
|
| 5.
|
Cash, E.,
M. Chamorro, and M. Brahic.
1986.
Quantitation, with a new assay, of Theiler's virus capsid protein in the central nervous system of mice.
J. Virol.
60:558-563[Abstract/Free Full Text].
|
| 6.
|
Cash, E.,
M. Chamorro, and M. Brahic.
1985.
Theiler's virus RNA and protein synthesis in the central nervous system of demyelinating mice.
Virology
144:290-294[Medline].
|
| 7.
|
Chen, H. H.,
W. P. Kong,
L. Zhang,
P. L. Ward, and R. P. Roos.
1995.
A picornaviral protein synthesized out of frame with the polyprotein plays a key role in a virus-induced immune-mediated demyelinating disease.
Nat. Med.
1:927-931[Medline].
|
| 8.
|
D'Souza, S. D.,
B. Bonetti,
V. Balasingam,
N. R. Cashman,
P. A. Barker,
A. B. Troutt,
C. S. Raine, and J. P. Antel.
1996.
Multiple sclerosis: Fas signaling in oligodendrocyte cell death.
J. Exp. Med.
184:2361-2370[Abstract/Free Full Text].
|
| 9.
|
Fu, J. L.,
S. Stein,
L. Rosenstein,
T. Bodwell,
M. Routbort,
B. L. Semler, and R. P. Roos.
1990.
Neurovirulence determinants of genetically engineered Theiler viruses.
Proc. Natl. Acad. Sci. USA
87:4125-4129[Abstract/Free Full Text].
|
| 10.
|
Ichikawa, H.,
K. Ota, and M. Iwata.
1996.
Increased Fas antigen on T cells in multiple sclerosis.
J. Neuroimmunol.
71:125-129[Medline].
|
| 11.
|
Jelachich, M. L., and H. L. Lipton.
1996.
Theiler's murine encephalomyelitis virus kills restrictive but not permissive cells by apoptosis.
J. Virol.
70:6856-6861[Abstract/Free Full Text].
|
| 12.
|
Jordan, J.,
M. F. Galindo,
J. H. Prehn,
R. R. Weichselbaum,
M. Beckett,
G. D. Ghadge,
R. P. Roos,
J. M. Leiden, and R. J. Miller.
1997.
p53 expression induces apoptosis in hippocampal pyramidal neuron cultures.
J. Neurosci.
17:1397-1405[Abstract/Free Full Text].
|
| 13.
|
Kaminski, A.,
M. T. Howell, and R. J. Jackson.
1990.
Initiation of encephalomyocarditis virus RNA translation: the authentic initiation site is not selected by a scanning mechanism.
EMBO J.
9:3753-3759[Medline].
|
| 14.
|
Karlik, S. J.,
S. Hyduk, and H. Horner.
1996.
Apoptosis throughout chronic EAE.
Multiple Sclerosis Clin. Lab. Res.
2:249.
|
| 15.
|
Kong, W.-P., and R. P. Roos.
1991.
Alternative translation initiation site in the DA strain of Theiler's murine encephalomyelitis virus.
J. Virol.
65:3395-3399[Abstract/Free Full Text].
|
| 16.
|
Levy, M.,
C. Aubert, and M. Brahic.
1992.
Theiler's virus replication in brain macrophages cultured in vitro.
J. Virol.
66:3188-3193[Abstract/Free Full Text].
|
| 16a.
| Lin, X., R. P. Roos, L. Pease, P. Wettstein, and M. Rodriguez. A Theiler's virus alternatively initiated protein
inhibits the generation of H-2K-restricted virus-specific toxicity.
Submitted for publication.
|
| 17.
|
Lin, X.,
N. R. Thiemann,
L. R. Pease, and M. Rodriguez.
1995.
VP1 and VP2 capsid proteins of Theiler's virus are targets of H-2D-restricted cytotoxic lymphocytes in the central nervous system of B10 mice.
Virology
214:91-99[Medline].
|
| 18.
|
Lindsley, M. D.,
R. Thiemann, and M. Rodriguez.
1991.
Cytotoxic T cells isolated from the central nervous systems of mice infected with Theiler's virus.
J. Virol.
65:6612-6620[Abstract/Free Full Text].
|
| 19.
|
Lipton, H. L.,
G. Twaddle, and M. L. Jelachich.
1995.
The predominant virus antigen burden is present in macrophages in Theiler's murine encephalomyelitis virus-induced demyelinating disease.
J. Virol.
69:2525-2533[Abstract].
|
| 20.
|
Macen, J. L.,
R. S. Garner,
P. Y. Musy,
M. A. Brooks,
P. C. Turner,
R. W. Moyer,
G. McFadden, and R. C. Bleackley.
1996.
Differential inhibition of the Fas- and granule-mediated cytolysis pathways by the orthopoxvirus cytokine response modifier A/SPI-2 and SPI-1 protein.
Proc. Natl. Acad. Sci. USA
93:9108-9113[Abstract/Free Full Text].
|
| 21.
|
Macen, J. L.,
K. A. Graham,
S. F. Lee,
M. Schreiber,
L. K. Boshkov, and G. McFadden.
1996.
Expression of the myxoma virus tumor necrosis factor receptor homologue and M11L genes is required to prevent virus-induced apoptosis in infected rabbit T lymphocytes.
Virology
218:232-237[Medline].
|
| 22.
|
McCombe, P. A.,
I. Nickson,
Z. Tabi, and M. P. Pender.
1996.
Apoptosis of V 8.2+ T lymphocytes in the spinal cord during recovery from experimental autoimmune encephalomyelitis induced in Lewis rats by inoculation with myelin basic protein.
J. Neurol. Sci.
139:1-6.
|
| 23.
|
McFarland, H. I.,
J. M. Critchfield,
M. K. Racke,
J. P. Mueller,
S. H. Nye,
S. A. Boehme, and M. J. Lenardo.
1995.
Amelioration of autoimmune reactions by antigen-induced apoptosis of T cells.
Adv. Exp. Med. Biol.
383:157-166[Medline].
|
| 24.
|
Nguyen, K. B.,
P. A. McCombe, and M. P. Pender.
1994.
Macrophage apoptosis in the central nervous system in experimental autoimmune encephalomyelitis.
J. Autoimmun.
7:145-152[Medline].
|
| 25.
|
Obuchi, M.,
Y. Ohara,
T. Takegami,
T. Murayama,
H. Takada, and H. Iizuka.
1997.
Theiler's murine encephalomyelitis virus subgroup strain-specific infection in a murine macrophage-like cell line.
J. Virol.
71:729-733[Abstract].
|
| 26.
|
Ohara, Y.,
S. Stein,
J. L. Fu,
L. Stillman,
L. Klaman, and R. P. Roos.
1988.
Molecular cloning and sequence determination of DA strain of Theiler's murine encephalomyelitis viruses.
Virology
164:245-255[Medline].
|
| 27.
|
Osborne, B. A.
1996.
Apoptosis and maintenance of homeostasis in the immune system.
Curr. Opin. Immunol.
8:245-254[Medline].
|
| 28.
|
Pearson, C. I.,
W. van Ewijk, and H. O. McDevitt.
1997.
Induction of apoptosis and T helper 2 (Th2) responses correlates with peptide affinity for the major histocompatibility complex in self-reactive T cell receptor transgenic mice.
J. Exp. Med.
185:583-599[Abstract/Free Full Text].
|
| 29.
|
Pena Rossi, C.,
A. McAllister,
L. Fiette, and M. Brahic.
1991.
Theiler's virus infection induces a specific cytotoxic T lymphocyte response.
Cell. Immunol.
138:341-348[Medline].
|
| 30.
|
Qi, Y., and M. C. Dal Canto.
1996.
Effect of Theiler's murine encephalomyelitis virus and cytokines on cultured oligodendrocytes and astrocytes.
J. Neurosci. Res.
45:364-374[Medline].
|
| 31.
|
Razvi, E. S., and R. M. Welsh.
1995.
Apoptosis in viral infections.
Adv. Virus Res.
45:1-60[Medline].
|
| 32.
|
Roos, R. P., and N. Casteel.
1992.
Determinants of neurological disease induced by Theiler's murine encephalomyelitis virus, p. 283-318.
In
R. P. Roos (ed.), Molecular neurovirology. Humana Press, Totowa, N.J.
|
| 33.
|
Roos, R. P.,
S. Stein,
Y. Ohara,
J. Fu, and B. L. Semler.
1989.
Infectious cDNA clones of the DA strain of Theiler's murine encephalomyelitis virus.
J. Virol.
63:5492-5496[Abstract/Free Full Text].
|
| 34.
|
Sabelko, K. A.,
K. A. Kelly,
M. H. Nahm,
A. H. Cross, and J. H. Russell.
1997.
Fas and Fas ligand enhance the pathogenesis of experimental allergic encephalomyelitis, but are not essential for immune privilege in the central nervous system.
J. Immunol.
159:3096-3099[Abstract].
|
| 35.
|
Sangar, D. V.,
S. E. Newton,
D. J. Rowlands, and B. E. Clarke.
1987.
All foot and mouth disease virus serotypes initiate protein synthesis at two separate AUGs.
Nucleic Acids Res.
15:3305-3315[Abstract/Free Full Text].
|
| 36.
|
Sato, S.,
S. L. Reiner,
M. A. Jensen, and R. P. Roos.
1997.
Central nervous system cytokine mRNA expression following Theiler's murine encephalomyelitis virus infection.
J. Neuroimmunol.
76:213-233[Medline].
|
| 37.
|
Sun, X. M.,
D. Dinsdale,
R. T. Snowden,
G. M. Cohen, and D. N. Skilleter.
1992.
Characterization of apoptosis in thymocytes isolated from dexamethasone-treated rats.
Biochem. Pharmacol.
44:2131-2137[Medline].
|
| 38.
|
Tesar, M.,
S. A. Harmon,
D. F. Summers, and E. Ehrenfeld.
1992.
Hepatitis A virus polyprotein synthesis initiates from two alternative AUG codons.
Virology
186:609-618[Medline].
|
| 39.
|
Tolskaya, E. A.,
L. I. Romanova,
M. S. Kolesnikova,
T. A. Ivannikova,
E. A. Smirnova,
N. T. Raikhlin, and V. I. Agol.
1995.
Apoptosis-inducing and apoptosis-preventing functions of poliovirus.
J. Virol.
69:1181-1189[Abstract].
|
| 40.
|
Tsunoda, I.,
G. I. B. Kurtz, and R. S. Fujinami.
1997.
Apoptosis in acute and chronic central nervous system disease induced by Theiler's murine encephalomyelitis virus.
Virology
228:388-393[Medline].
|
| 41.
|
Waldner, H.,
R. A. Sobel,
E. Howard, and V. K. Kuchroo.
1997.
Fas- and FasL-deficient mice are resistant to induction of autoimmune encephalomyelitis.
J. Immunol.
159:3100-3103[Abstract].
|
| 42.
|
Zhang, L.,
S. Sato,
J. I. Kim, and R. P. Roos.
1995.
Theiler's virus as a vector for foreign gene delivery.
J. Virol.
69:3171-3175[Abstract].
|
Journal of Virology, November 1998, p. 8605-8612, Vol. 72, No. 11
0022-538X/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Romanova, L. I., Lidsky, P. V., Kolesnikova, M. S., Fominykh, K. V., Gmyl, A. P., Sheval, E. V., Hato, S. V., van Kuppeveld, F. J. M., Agol, V. I.
(2009). Antiapoptotic Activity of the Cardiovirus Leader Protein, a Viral "Security" Protein. J. Virol.
83: 7273-7284
[Abstract]
[Full Text]
-
Taniura, N., Saito, M., Okuwa, T., Saito, K., Ohara, Y.
(2009). Different Subcellular Localization of Theiler's Murine Encephalomyelitis Virus Leader Proteins of GDVII and DA Strains in BHK-21 Cells. J. Virol.
83: 6624-6630
[Abstract]
[Full Text]
-
Fan, J., Son, K.-N., Arslan, S. Y., Liang, Z., Lipton, H. L.
(2009). Theiler's Murine Encephalomyelitis Virus Leader Protein Is the Only Nonstructural Protein Tested That Induces Apoptosis When Transfected into Mammalian Cells. J. Virol.
83: 6546-6553
[Abstract]
[Full Text]
-
Blinkova, O., Kapoor, A., Victoria, J., Jones, M., Wolfe, N., Naeem, A., Shaukat, S., Sharif, S., Alam, M. M., Angez, M., Zaidi, S., Delwart, E. L.
(2009). Cardioviruses Are Genetically Diverse and Cause Common Enteric Infections in South Asian Children. J. Virol.
83: 4631-4641
[Abstract]
[Full Text]
-
Ricour, C., Delhaye, S., Hato, S. V., Olenyik, T. D., Michel, B., van Kuppeveld, F. J. M., Gustin, K. E., Michiels, T.
(2009). Inhibition of mRNA export and dimerization of interferon regulatory factor 3 by Theiler's virus leader protein. J. Gen. Virol.
90: 177-186
[Abstract]
[Full Text]
-
Chiu, C. Y., Greninger, A. L., Kanada, K., Kwok, T., Fischer, K. F., Runckel, C., Louie, J. K., Glaser, C. A., Yagi, S., Schnurr, D. P., Haggerty, T. D., Parsonnet, J., Ganem, D., DeRisi, J. L.
(2008). Identification of cardioviruses related to Theiler's murine encephalomyelitis virus in human infections. Proc. Natl. Acad. Sci. USA
105: 14124-14129
[Abstract]
[Full Text]
-
Asakura, K., Murayama, H., Himeda, T., Ohara, Y.
(2007). Expression of L* protein of Theiler's murine encephalomyelitis virus in the chronic phase of infection. J. Gen. Virol.
88: 2268-2274
[Abstract]
[Full Text]
-
Paul, S., Michiels, T.
(2006). Cardiovirus leader proteins are functionally interchangeable and have evolved to adapt to virus replication fitness.. J. Gen. Virol.
87: 1237-1246
[Abstract]
[Full Text]
-
Asakura, K., Murayama, H., Himeda, T., Ohara, Y.
(2002). Epitope-Tagged L* Protein of Theiler's Murine Encephalomyelitis Virus Is Expressed in the Central Nervous System in the Acute Phase of Infection. J. Virol.
76: 13049-13054
[Abstract]
[Full Text]
-
van Eyll, O., Michiels, T.
(2002). Non-AUG-Initiated Internal Translation of the L* Protein of Theiler's Virus and Importance of This Protein for Viral Persistence. J. Virol.
76: 10665-10673
[Abstract]
[Full Text]
-
van Eyll, O., Michiels, T.
(2000). Influence of the Theiler's Virus L* Protein on Macrophage Infection, Viral Persistence, and Neurovirulence. J. Virol.
74: 9071-9077
[Abstract]
[Full Text]
-
Agol, V. I., Belov, G. A., Bienz, K., Egger, D., Kolesnikova, M. S., Romanova, L. I., Sladkova, L. V., Tolskaya, E. A.
(2000). Competing Death Programs in Poliovirus-Infected Cells: Commitment Switch in the Middle of the Infectious Cycle. J. Virol.
74: 5534-5541
[Abstract]
[Full Text]
-
Obuchi, M., Yamamoto, J., Odagiri, T., Uddin, M. N., Iizuka, H., Ohara, Y.
(2000). L* Protein of Theiler's Murine Encephalomyelitis Virus Is Required for Virus Growth in a Murine Macrophage-Like Cell Line. J. Virol.
74: 4898-4901
[Abstract]
[Full Text]
-
Badshah, C., Calenoff, M. A., Rundell, K.
(2000). The Leader Polypeptide of Theiler's Murine Encephalomyelitis Virus Is Required for the Assembly of Virions in Mouse L Cells. J. Virol.
74: 875-882
[Abstract]
[Full Text]
-
Yamasaki, K., Weihl, C. C., Roos, R. P.
(1999). Alternative Translation Initiation of Theiler's Murine Encephalomyelitis Virus. J. Virol.
73: 8519-8526
[Abstract]
[Full Text]
-
Lin, X., Roos, R. P., Pease, L. R., Wettstein, P., Rodriguez, M.
(1999). A Theiler's Virus Alternatively Initiated Protein Inhibits the Generation of H-2K-Restricted Virus-Specific Cytotoxicity. J. Immunol.
162: 17-24
[Abstract]
[Full Text]